trial

Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia

NCTId NCT02661347
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Withdrawn
Enrollment 0 (actual)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2016-12-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-02
Primary completion
2016-12-01
Eligibility
ALL · 15 Years · 40 Years

Interventions & indications

Drugs
RisperidoneTDCS

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor

Investigators

1
Deepak C D'Souza, M.D.Principal Investigator

Sites

1 total
Glen Oaks, United States

Facts & assertions

4 sourced
Enrollment
0
Phase
NA
Primary Completion Date
2016-12-01
Status
WITHDRAWN
relationships
The graph out of here
drug
Risperidone
drug
TDCS
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
indication
Schizophreniform
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Deepak C D'Souza, M.D.
person